We believe that Baxter International’s (BAX) focus on life-sustaining
products insulates its results from the current economic downturn and provide investors with good quality returns on a risk-adjusted basis.

The company has a strong product pipeline, with a number of promising products in the final stages of clinical trials. Baxter’s strong market position is demonstrated in its recent quarterly performance that came ahead of guidance, while earnings exceeded
the Zacks Consensus Estimate.

We believe that investors will benefit by adding this stock to their portfolio.Zacks Investment Research